Finance

Lists
GIS:FRA
Gilead Sciences, Inc
130,88 €
+0,28%
(+0,36) 1D
9 ოქტ, 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for GIS...
Open
130,88 €
High
130,88 €
Low
130,88 €
Mkt. cap
187,44 მლრ.
Avg. vol.
398,00
Volume
0,00
52-wk high
134,58 €
52-wk low
97,79 €
No. of employees
17 ათ.
Open
130,88 €
High
130,88 €
Low
130,88 €
Mkt. cap
187,44 მლრ.
Avg. vol.
398,00
Volume
0,00
52-wk high
134,58 €
52-wk low
97,79 €
No. of employees
17 ათ.
News stories
From web sources and news partners
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade. In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100. The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEOდენიელ ო'დეი
Employees17 ათ.
Founded22 ივნ. 1987
HeadquartersFoster City, კალიფორნია, ამერიკის შეერთებული შტატები
Sector-
Websitegilead.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
7,77 მლრდ.
7,92 მლრდ.
6,96 მლრდ.
7,80 მლრდ.
Cost of goods sold
1,57 მლრდ.
1,62 მლრდ.
1,44 მლრდ.
1,58 მლრდ.
Cost of revenue
1,57 მლრდ.
1,62 მლრდ.
1,44 მლრდ.
1,58 მლრდ.
Research and development expenses
1,33 მლრდ.
1,57 მლრდ.
1,36 მლრდ.
1,69 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,35 მლრდ.
1,78 მლრდ.
1,43 მლრდ.
1,91 მლრდ.
Operating expense
2,69 მლრდ.
3,34 მლრდ.
2,78 მლრდ.
3,60 მლრდ.
Total operating expenses
4,26 მლრდ.
4,96 მლრდ.
4,23 მლრდ.
5,18 მლრდ.
Operating income
3,51 მლრდ.
2,96 მლრდ.
2,73 მლრდ.
2,63 მლრდ.
Other non operating income
-23,00 მლნ.
51,00 მლნ.
-8,00 მლნ.
-
EBT including unusual items
3,64 მლრდ.
2,08 მლრდ.
2,58 მლრდ.
-10,25 მლრდ.
EBT excluding unusual items
3,34 მლრდ.
2,80 მლრდ.
2,59 მლრდ.
2,42 მლრდ.
Income tax expense
589,00 მლნ.
-105,00 მლნ.
559,00 მლნ.
242,00 მლნ.
Effective tax rate
16,18%
-5,05%
21,67%
-2,36%
Other operating expenses
-
-
-
-
Net income
3,05 მლრდ.
2,18 მლრდ.
2,02 მლრდ.
-10,50 მლრდ.
Net profit margin
39,28%
27,55%
29,04%
-134,51%
Earnings per share
2,47
1,86
2,03
-6,75
Interest and investment income
88,00 მლნ.
95,00 მლნ.
95,00 მლნ.
45,00 მლნ.
Interest expense
-256,00 მლნ.
-255,00 მლნ.
-240,00 მლნ.
-247,00 მლნ.
Net interest expenses
-168,00 მლნ.
-160,00 მლნ.
-145,00 მლნ.
-202,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
4,20 მლრდ.
3,65 მლრდ.
3,42 მლრდ.
3,33 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები